Key Takeaways
- Inify Laboratories AB, a Sweden-based cancer diagnostics company listed on Euronext Growth Oslo (ticker: INIFY)
- The company closed a fully guaranteed Repair Issue raising gross proceeds of approximately NOK 8 million (~$725.7K USD), issuing 2,304,563 new shares at NOK 3.50 per share
- Capital raised to support ongoing UK laboratory buildout and strengthen working capital as Inify targets the UK’s ~120,000 annual prostate cancer diagnostics market, estimated at 6x the size of Sweden’s
- The global digital pathology market is valued at approximately $1.47 billion in 2026 and is projected to grow to $5.75 billion by 2034 at an 18.56% CAGR
Quick Recap
Breaking news from the Euronext Growth Oslo exchange confirms that Inify Laboratories AB has completed a fully guaranteed Repair Issue, raising gross proceeds of approximately NOK 8 million (~$725.7K USD) through the issuance of 2,304,563 new shares priced at NOK 3.50 per share. The announcement was sourced via @Parsers_vc on X (formerly Twitter), with official filings confirming the final allocation results dated January 27, 2026. The Repair Issue was backed 100% by guarantors Monsun AS and Auris AS, entities controlled by the company’s two largest shareholders, Gallivant S.à r.l. and Tauri AS.
Inside the Raise: Structure, Terms, and Strategic Intent
The Repair Issue was the follow-on tranche of a broader capital raise that Inify announced on November 12, 2025, which also included a larger private placement. The Repair Issue was structured specifically for existing shareholders who did not participate in the private placement and held fewer than 1,000,000 shares in the company, with eligible shareholders receiving 0.3621 non-tradable subscription rights per share held as of the December 18, 2025 record date.
At the close of the subscription window on January 26, 2026, the company received valid subscriptions for 1,256,658 shares from eligible shareholders, with the remaining 1,047,905 shares allocated to the guarantors, Monsun AS (898,204 shares) and Auris AS (149,701 shares). The capital is earmarked to fund Inify’s UK laboratory operations, which were being built out with a target of opening for clinical activities in early 2026, as well as to strengthen the company’s general working capital position.
Inify’s Swedish laboratory at Campus Solna already serves prostate cancer diagnostics, and the company held approximately 80% market share of prostate diagnostics in the Stockholm region by end-2024, with full-year 2024 revenues of SEK 13.7 million compared to just SEK 1.2 million the year prior, representing a 472% year-over-year surge. Q3 2025 net sales reached SEK 4,991 thousand, up 76% year-over-year, and the company delivered its first gastrointestinal patient samples in the quarter.
Pathology is Broken, and Capital is Flowing
The funding arrives at a critical inflection point for clinical pathology globally. Rising cancer incidence, an aging population, increasing screening programmes, and a declining number of practicing pathologists are collectively putting clinical pathology departments under sustained strain. The WHO projects global new cancer cases to reach 35 million annually by 2050, up from roughly 20 million in 2022, intensifying the diagnostic workload.
The global digital pathology market was valued at approximately $1.3 billion in 2025 and is forecast to reach between $2.76 billion and $5.75 billion by 2034-2035 depending on the research model, with CAGR estimates ranging from approximately 8% to 18.56%. The US and European markets combined were valued at $717 million in 2025 and are projected to approach $1.49 billion by 2035. North America currently leads with a roughly 36-41% market share, but the UK represents a particularly attractive expansion corridor given its NHS backlog pressures.
Inify’s push into the UK is well-timed. The UK market for prostate cancer diagnostics alone is estimated at approximately 120,000 patient cases annually, roughly six times the volume of the Swedish market. Inify’s UK laboratory has the planned capacity to process approximately 100,000 patient cases per year at full build-out. The company has been actively engaged with both NHS and private healthcare providers, reporting a “very positive” reception for its patient pathway model.
Competitive Landscape
Inify vs. Comparable Histopathology Diagnostics Startups
| Feature / Metric | Inify Laboratories (SE) | Deciphex (IE) | Gestalt Diagnostics (US) |
| Core Model | Specialist lab services (histopathology, prostate + GI cancer diagnostics) with proprietary AI | Dual-platform: Diagnexia (clinical diagnostics network) + Patholytix (pharma research) | Cloud-based PathFlow enterprise platform for digital workflow + AI biomarker scoring |
| Latest Funding Round | ~$725.7K Repair Issue (Jan 2026) | €15M venture debt from Claret Capital (Oct 2025), following €31M Series C (Jan 2025) | $7.5M Series A (April 2025) |
| Total Funding Stage | Public (Euronext Growth Oslo, listed 2022); multiple share issues | Growth-stage; Series C + debt (€46M+ cumulative) | Early growth; Series A completed |
| Geographic Focus | Sweden + UK (expanding) | US, UK, EU, Canada, Japan | US (primary), global scale ambition |
| AI Integration | Proprietary AI, pathologist-assisted; world-leading precision in prostate diagnostics per clinical evaluations | AI automates routine pathology tasks; claims up to 40% speed improvement for pathologists | AI algorithms for biomarker scoring; FDA clearance pursuit ongoing |
| Pathologist Network | In-house pathologists + AI workflow | 250+ global subspecialty pathologists; 97,000 cases/year | Platform-based; integrates with existing lab systems |
| Revenue (Latest) | SEK 4,991K (~$470K) in Q3 2025; SEK 13.7M for full-year 2024 | Not publicly disclosed; 97,000+ cases/year volume | Not publicly disclosed |
| Regulatory Status | Accredited clinical lab in Sweden; UK lab in build-out | Operating across US, UK, EU, Canada, Japan | Pursuing FDA clearance |
Strategic Read
Inify leads in vertical integration: it operates its own laboratory with a proprietary AI stack and targets the full patient pathway from logistics to final report, a model that differentiates it from pure-software platforms like Gestalt Diagnostics.
Deciphex, however, holds a material edge in scale and geographic reach, with a 250+ pathologist network processing nearly 97,000 cases annually across five geographies and over €46 million in cumulative funding. For high-volume pharma research use cases, Deciphex’s Patholytix platform has no direct equivalent at Inify’s current stage, while Gestalt competes primarily as a workflow platform rather than a clinical diagnostics provider, making it more of a software-layer play than a direct head-to-head rival.
Bayelsa Watch’s Takeaway
I will be direct here: on paper, $725.7K is a number that might make some readers scroll past this story. In my experience covering medtech and digital health funding rounds, pre-revenue or early-revenue diagnostics companies routinely raise in the tens of millions for a single tranche, so this figure demands context before forming a verdict.
What I think makes this deal interesting is not the dollar amount but the structural discipline behind it. Inify is a publicly listed entity on Euronext Growth Oslo with a fully guaranteed raise backed by its two largest shareholders, meaning the company did not need to chase external venture capital to fund this tranche. That speaks to a tight capital allocation mindset and a shareholder base that is genuinely committed to the UK expansion thesis rather than diluting the cap table with opportunistic outside money.
